Table 3.
Subgroup analyses of the association between metabolic health-obesity (defined by %BF) phenotypes and kidney stones.
| Subgroup† | MHN OR (95% CI) | MHOW OR (95% CI) | MHO OR (95% CI) | MUN OR (95% CI) | MUOW OR (95% CI) | MUO OR (95% CI) | P for interaction |
|---|---|---|---|---|---|---|---|
| Sex | 0.395 | ||||||
| Male | Reference | 0.45 (0.07–2.92) | 1.35 (0.30–6.13) | 0.54 (0.17–1.70) | 1.19 (0.39–3.63) | 1.63 (0.56–4.79) | |
| Female | Reference | 3.18 (0.75–13.39) | 4.87 (1.34–17.69) | 5.16 (1.28–20.83) | 5.29 (1.48–18.93) | 6.35 (1.94–20.75) | |
| Age | 0.082 | ||||||
| <40 years | Reference | 2.94 (0.79–10.86) | 4.32 (1.23–15.13) | 5.18 (1.41–18.94) | 4.88 (1.59–14.97) | 5.57 (1.78–17.44) | |
| ≥40 years | Reference | 0.18 (0.03–1.13) | 1.50 (0.25–9.12) | 0.27 (0.05–1.53) | 0.86 (0.24–3.03) | 1.28 (0.36–4.52) | |
| Smoking status | 0.947 | ||||||
| Current smokers | Reference | 1.16 (0.06–23.13) | 2.48 (0.31–19.64) | 1.61 (0.21–12.52) | 2.21 (0.32–15.46) | 3.12 (0.46–21.11) | |
| Non-current smokers | Reference | 1.57 (0.51–4.87) | 3.02 (1.06–8.64) | 2.22 (0.69–7.17) | 2.90 (1.14–7.41) | 3.51 (1.48–8.33) | |
| Physical activity status | 0.271 | ||||||
| Active | Reference | 2.12 (0.10–11.22) | 3.89 (0.95–15.88) | 3.22 (0.71–14.60) | 2.88 (0.74–11.22) | 3.31 (0.87–12.52) | |
| Inactive | Reference | 1.13 (0.31–4.20) | 2.37 (0.72–7.86) | 0.87 (0.24–3.21) | 2.65 (0.92–7.64) | 3.68 (1.29–10.50) |
%BF, percent body fat; MHN, metabolically healthy normal weight; MHOW, metabolically healthy overweight; MHO, metabolically healthy obesity; MUN, metabolically unhealthy normal weight; MUOW, metabolically unhealthy overweight; MUO, metabolically unhealthy obesity; OR, odds ratio; CI, confidence interval. †Multivariable model was adjusted for age (except for age subgroups), sex (except for sex subgroups), race and ethics, education level, smoking status (except for smoking status subgroups), alcohol consumption, physical activity (except for physical activity subgroups), daily water intake, CKD stage 3–5, and hyperuricemia.